[1]
|
徐杰茹, 陈磊, 张敏, 姚承志, 王冕, 让蔚清. 1990-2019年中国卵巢癌发病与死亡趋势及其年龄-时期-队列模型分析[J]. 中国肿瘤, 2022, 31(4): 276-283.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[3]
|
Berek, J.S., Renz, M., Kehoe, S., Kumar, L. and Friedlander, M. (2021) Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2021 Update. International Journal of Gynecology & Obstetrics, 155, 61-85.
https://doi.org/10.1002/ijgo.13878
|
[4]
|
Vanderpuye, V.D., Clemenceau, J.R.V., Temin, S., Aziz, Z., Burke, W.M., Cevallos, N.L., Chuang, L.T., Colgan, T.J., Del Carmen, M.G., Fujiwara, K., Kohn, E.C., Gonzáles Nogales, J.E., Kon-ney, T.O., Mukhopadhyay, A., Paudel, B.D., Tóth, I., Wilailak, S. and Ghebre, R.G. (2021) Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline. JCO Global Oncology, 7, 1032-1066.
https://doi.org/10.1200/GO.21.00085
|
[5]
|
Jiang, X., Tang, H. and Chen, T. (2018) Epidemiology of Gynecologic Cancers in China. Journal of Gynecologic Oncology, 29, e7. https://doi.org/10.3802/jgo.2018.29.e7
|
[6]
|
Hoeijmakers J.H. (2001) Genome Maintenance Mechanisms for Pre-venting Cancer. Nature, 411, 366-374.
https://doi.org/10.1038/35077232
|
[7]
|
da Cunha Colombo Bonadio, R.R., Fogace, R.N., Miranda, V.C. and Diz, M.D.P.E. (2018) Homologous Recombination Deficiency In Ovarian Cancer: A Review of Its Epidemiology and Man-agement. Clinics, 73, e450s.
https://doi.org/10.6061/clinics/2018/e450s
|
[8]
|
Ke, Y., Wang, C., Zhang, J., Zhong, X., Wang, R., Zeng, X. and Ba, X. (2019) The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and beyond. Cells, 8, Article No. 1047.
https://doi.org/10.3390/cells8091047
|
[9]
|
Selvakumaran, M., Pisarcik, D.A., Bao, R., Yeung, A.T. and Hamilton, T.C. (2003) Enhanced Cisplatin Cytotoxicity by Disturbing the Nucleotide Excision Repair Pathway in Ovarian Cancer Cell Lines. Cancer Research, 63, 1311-1316.
|
[10]
|
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Macpherson, E., Watkins, C., Carmichael, J. and Matulonis, U. (2012) Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. The New Eng-land Journal of Medicine, 366, 1382-1392.
https://doi.org/10.1056/NEJMoa1105535
|
[11]
|
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C.L., Meier, W., Shapira-Frommer, R., Safra, T., Matei, D., Fielding, A., Spencer, S., Dougherty, B., Orr, M., Hodgson, D., Barrett, J.C. and Matulonis, U. (2014) Olaparib Maintenance Therapy in Patients with Plati-num-Sensitive Relapsed Serous Ovarian Cancer: A Preplanned Retrospective Analysis of Outcomes by BRCA Status in a Randomised Phase 2 Trial. The Lancet Oncology, 15, 852-861. https://doi.org/10.1016/S1470-2045(14)70228-1
|
[12]
|
Pujade-Lauraine, E., Ledermann, J.A., Selle, F., Gebski, V., Penson, R.T., Oza, A.M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., Friedlander, M., Colombo, N., Harter, P., Fujiwara, K., Ray-Coquard, I., Banerjee, S., Liu, J., Lowe, E.S., Bloomfield, R. and Pautier, P. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1274-1284. https://doi.org/10.1016/S1470-2045(17)30469-2
|
[13]
|
Poveda, A., Floquet, A., Ledermann, J.A., Asher, R., Penson, R.T., Oza, A.M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., Baldoni, A., Park-Simon, T.W., Tamura, K., Sonke, G.S., Lisyanskaya, A., Kim, J.H., Filho, E.A., Milenkova, T., Lowe, E.S., Rowe, P., et al. (2021) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/Engot-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 22, 620-631.
https://doi.org/10.1016/S1470-2045(21)00073-5
|
[14]
|
Penson, R.T., Valencia, R.V., Cibula, D., Colombo, N., Leath 3rd, C.A., Bidziński, M., Kim, J.W., Nam, J.H., Madry, R., Hernández, C., Mora, P.A.R., Ryu, S.Y., Milenkova, T., Lowe, E.S., Barker, L. and Scambia, G. (2020) Olaparib Versus Nonplatinum Chemotherapy in Patients with Plati-num-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. Journal of Clinical Oncology, 38, 1164-1174.
https://doi.org/10.1200/JCO.19.02745
|
[15]
|
DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G.S., Gourley, C., Oza, A., Gonzá-lez-Martín, A., Aghajanian, C., Bradley, W., Mathews, C., Liu, J., McNamara, J., Lowe, E.S., et al. (2023) Overall Sur-vival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. Journal of Clinical Oncology, 41, 609-617. https://doi.org/10.1200/JCO.22.01549
|
[16]
|
Mirza, M.R., Monk, B.J., Herrstedt, J., Oza, A.M., Mahner, S., Re-dondo, A., Fabbro, M., Ledermann, J.A., Lorusso, D., Vergote, I., Ben-Baruch, N.E., Marth, C., Mądry, R., Christensen, R.D., Berek, J.S., Dørum, A., Tinker, A.V., du Bois, A., González-Martín, A., Follana, P., et al. (2016) Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England Journal of Medicine, 375, 2154-2164. https://doi.org/10.1056/NEJMoa1611310
|
[17]
|
Wu, X.H., Zhu, J.Q., Yin, R.T., Yang, J.X., Liu, J.H., Wang, J., Wu, L.Y., Liu, Z.L., Gao, Y.N., Wang, D.B., Lou, G., Yang, H.Y., Zhou, Q., Kong, B.H., Huang, Y., Chen, L.P., Li, G.L., An, R.F., Wang, K., Zhang, Y., et al. (2021) Niraparib Maintenance Therapy in Patients with Plati-num-Sensitive Recurrent Ovarian Cancer Using an Individualized Starting Dose (NORA): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Annals of Oncology, 32, 512-521. https://doi.org/10.1016/j.annonc.2020.12.018
|
[18]
|
González-Martín, A., Pothuri, B., Vergote, I., DePont Christen-sen, R., Graybill, W., Mirza, M.R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Baumann, K., Jardon, K., Re-dondo, A., Moore, R.G., Vulsteke, C., O’Cearbhaill, R.E., Lund, B., Backes, F., Barretina-Ginesta, P., Haggerty, A.F., et al. (2019) Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. The New England Journal of Medi-cine, 381, 2391-2402.
https://doi.org/10.1056/NEJMoa1910962
|
[19]
|
Nakai, H. and Matsumura, N. (2022) The Roles and Limitations of Bevacizumab in the Treatment of Ovarian Cancer. International Journal of Clinical Oncology, 27, 1120-1126. https://doi.org/10.1007/s10147-022-02169-x
|
[20]
|
Arora, S., Balasubramaniam, S., Zhang, H., Berman, T., Narayan, P., Suzman, D., Bloomquist, E., Tang, S., Gong, Y., Sridhara, R., Turcu, F.R., Chatterjee, D., Saritas-Yildirim, B., Ghosh, S., Philip, R., Pathak, A., Gao, J.J., Amiri-Kordestani, L., Pazdur, R. and Beaver, J.A. (2021) FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. The Oncologist, 26, e164-e172.
|
[21]
|
Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Mannel, R.S., Homesley, H.D., Fowler, J., Greer, B.E., Boente, M., Birrer, M.J. and Liang, S.X. (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. The New England Jour-nal of Medicine, 365, 2473-2483.
https://doi.org/10.1056/NEJMoa1104390
|
[22]
|
Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pu-jade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M.R., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. https://doi.org/10.1056/NEJMoa1103799
|
[23]
|
Oza, A.M., Cook, A.D., Pfisterer, J., Embleton, A., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Park-Simon, T.W., Rustin, G., Joly, F., Mirza, M.R., Plante, M., Quinn, M., Poveda, A., Jayson, G.C., Stark, D., Swart, A.M., et al. (2015) Standard Chemo-therapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. The Lancet Oncology, 16, 928-936. https://doi.org/10.1016/S1470-2045(15)00086-8
|
[24]
|
中华医学会妇科肿瘤学分会. 妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南(2022版) [J]. 现代妇产科进展, 2023, 32(1): 1-13.
|
[25]
|
Strickland, K.C., Howitt, B.E., Shukla, S.A., Rodig, S., Ritterhouse, L.L., Liu, J.F., Garber, J.E., Chowdhury, D., Wu, C.J., D’Andrea, A.D., Matulonis, U.A. and Konstantinopoulos, P.A. (2016) Association and Prognostic Significance of BRCA1/2-Mutation Status with Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes and Expression of PD-1/PD-L1 in high Grade Serous Ovarian Cancer. Oncotarget, 7, 13587-13598.
https://doi.org/10.18632/oncotarget.7277
|
[26]
|
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., Selle, F., Sehouli, J., Lorusso, D., Guerra Alía, E.M., Reinthaller, A., Nagao, S., Lefeuvre-Plesse, C., Canzler, U., Scambia, G., Lortholary, A., et al. (2019) Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. The New England Journal of Medicine, 381, 2416-2428. https://doi.org/10.1056/NEJMoa1911361
|
[27]
|
Lan, C.Y., Wang, Y., Xiong, Y., Li, J.D., Shen, J.X., Li, Y.F., Zheng, M., Zhang, Y.N., Feng, Y.L., Liu, Q., Huang, H.Q. and Huang, X. (2018) Apatinib Combined with Oral Etopo-side in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (AEROC): A Phase 2, Single-Arm, Prospective Study. The Lancet Oncology, 19, 1239-1246. https://doi.org/10.1016/S1470-2045(18)30349-8
|
[28]
|
Pardoll D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[29]
|
Varga, A., Piha-Paul, S., Ott, P.A., Mehnert, J.M., Berton-Rigaud, D., Morosky, A., Yang, P., Ruman, J. and Matei, D. (2019) Pembrolizumab in Patients with Programmed Death Ligand 1-Positive Advanced Ovarian Cancer: Analysis of KEYNOTE-028. Gynecologic Oncology, 152, 243-250. https://doi.org/10.1016/j.ygyno.2018.11.017
|
[30]
|
Kverneland, A.H., Pedersen, M., Westergaard, M.C.W., Nielsen, M., Borch, T.H., Olsen, L.R., Aasbjerg, G., Santegoets, S.J., van der Burg, S.H., Milne, K., Nelson, B.H., Met, Ö., Donia, M. and Svane, I.M. (2020) Adoptive Cell Therapy in Combination with Checkpoint Inhibitors in Ovarian Cancer. Oncotarget, 11, 2092-2105.
https://doi.org/10.18632/oncotarget.27604
|
[31]
|
Geukes Foppen, M.H., Donia, M., Svane, I.M. and Haanen, J.B. (2015) Tumor-Infiltrating Lymphocytes for the Treatment of Metastatic Cancer. Molecular Oncology, 9, 1918-1935. https://doi.org/10.1016/j.molonc.2015.10.018
|
[32]
|
Rosenberg, S.A., Spiess, P. and Lafreniere, R. (1986) A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes. Science, 233, 1318-1321. https://doi.org/10.1126/science.3489291
|
[33]
|
Freedman, R.S., Tomasovic, B., Templin, S., Atkinson, E.N., Kudelka, A., Edwards, C.L. and Platsoucas, C.D. (1994) Large-Scale Expansion in Interleukin-2 of Tumor-Infiltrating Lymphocytes from Patients with Ovarian Carcinoma for Adoptive Immunotherapy. Journal of Immunological Methods, 167, 145-160.
https://doi.org/10.1016/0022-1759(94)90084-1
|
[34]
|
Ikarashi, H., Fujita, K., Takakuwa, K., Kodama, S., Tokunaga, A., Takahashi, T. and Tanaka, K. (1994) Immunomodulation in Patients with Epithelial Ovarian Cancer after Adoptive Transfer of Tumor-Infiltrating Lymphocytes. Cancer Research, 54, 190-196.
|
[35]
|
Chen, J., Hu, J., Gu, L., Ji, F., Zhang, F., Zhang, M., Li, J., Chen, Z., Jiang, L., Zhang, Y., Shi, R., Ma, L., Jia, S., Zhang, Y., Zhang, Q., Liang, J., Yao, S., Hu, Z. and Guo, Z. (2023) Anti-Mesothelin CAR-T Immunotherapy in Patients with Ovarian Cancer. Cancer Immunology, Immunotherapy, 72, 409-425. https://doi.org/10.1007/s00262-022-03238-w
|
[36]
|
Rodriguez, G.M., Galpin, K.J.C., McCloskey, C.W. and Vanderhyden, B.C. (2018) The Tumor Microenvironment of Epithelial Ovarian Cancer and Its In-fluence on Response to Immunotherapy. Cancers, 10, Article No. 242.
https://doi.org/10.3390/cancers10080242
|